| Autor: |
Borstnar Simona, Palacova Marketa, Łacko Aleksandra, Timcheva Constanta, Gal-Yam Einav Nili, Papazisis Konstantinos, Beniak Juraj, Kudela Pavol, Rubovszky Gábor |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Radiology and Oncology, Vol 56, Iss 2, Pp 238-247 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
1581-3207 |
| DOI: |
10.2478/raon-2022-0020 |
| Popis: |
The CDK4/6 inhibitor, ribociclib in combination with endocrine therapy significantly improved progression-free survival in the first line setting in post-menopausal patients with HR+/HER2− advanced breast cancer (ABC) in a pivotal phase 3, placebo-controlled trial (MONALEESA-2) and demonstrated superior overall survival in premenopausal patients with HR+/HER2− ABC (MONALEESA-7). The multinational, phase 3b, CompLEEment-1 trial, which assessed the safety and efficacy of ribociclib plus letrozole in a broader population of patients who have not received prior endocrine therapy for advanced disease, is the largest phase 3 clinical trial to date to evaluate the safety and efficacy of a CDK4/6 inhibitor. We report a subanalysis of data from patients (N = 339) enrolled in the central and south European countries of the SERCE (Southern Europe, RUC, Central Europe) cluster of CompLEEment-1. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
